Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
21.72
+0.77 (3.68%)
At close: Jul 25, 2025, 4:00 PM
21.71
-0.01 (-0.05%)
After-hours: Jul 25, 2025, 7:44 PM EDT
Beam Therapeutics Employees
Beam Therapeutics had 483 employees as of December 31, 2024. The number of employees increased by 47 or 10.78% compared to the previous year.
Employees
483
Change (1Y)
47
Growth (1Y)
10.78%
Revenue / Employee
$131,631
Profits / Employee
-$801,952
Market Cap
2.12B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 483 | 47 | 10.78% |
| Dec 31, 2023 | 436 | -71 | -14.00% |
| Dec 31, 2022 | 507 | 166 | 48.68% |
| Dec 31, 2021 | 341 | 160 | 88.40% |
| Dec 31, 2020 | 181 | 63 | 53.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BEAM News
- 5 weeks ago - Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases - Seeking Alpha
- 6 weeks ago - Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - GlobeNewsWire
- 2 months ago - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 2 months ago - Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress - GlobeNewsWire
- 2 months ago - Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 2 months ago - Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire